Calan
Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories
Calan, Urine
Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories
Calando Pharmaceuticals Announces Preclinical Efficacy and Safety
Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
Data Indicate Significant Anti-Tumor Effects of Targeted, SystemicsiRNA Therapeutic at Doses Significantly Lower Than the Limits ofSafe Administrations in Rodent and Non-Human Primates PASADENA, Calif., April 16, 2007 /PRNewswire/ --
CalandoPharmaceuticals, a leading siRNA therapeutics company and amajority-owned subsidiary of Arrowhead Research Corporationpresented positive results of pr...
Arrowhead Subsidiaries Insert & Calando Present Data on
Cyclosert Drug Delivery System at AACR Meeting
Novel Systems May Provide Cancer Patients With Improved Potentialto Battle Their Disease PASADENA, Calif., April 16, 2007 /PRNewswire-FirstCall/ --Arrowhead Research Corporation announced today that two of itsmajority-owned subsidiaries, Insert Therapeutics Inc. and
CalandoPharmaceuticals Inc., are presenting data at the 2007 AmericanAssociation for Cancer Research (AACR) Annual Meeting....
Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study
Showing Anti-Cancer Effect with Lead RNAi Candidate
PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - Arrowhead ResearchCorporation (NASDAQ: ARWR) announced the publication by itsmajority-owned subsidiary
Calando Pharmaceuticals, Inc. of a studydemonstrating the anti-proliferative effect of the siRNA sequenceselected as the therapeutic component of its lead anti-cancercompound, CALAA-01. The paper, entitled "Potent siRNA Inhibitors of Ribon...
Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect
with Lead RNAi Candidate
PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 -
CalandoPharmaceuticals, a leading siRNA therapeutics company and amajority-owned subsidiary of Arrowhead Research Corporation(NASDAQ:ARWR) announced the publication of a study demonstratingthe anti-proliferative effect of the siRNA sequence selected as thetherapeutic component of its lead anti-cancer compound, CALAA-01. The paper, entitled...
Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on
Targeted, Systemic Delivery of siRNA
PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - ArrowheadResearch Corporation (NASDAQ:ARWR) announced today thatmajority-owned subsidiary
Calando Pharmaceuticals has publishedresults in the Proceedings of the National Academy of Sciences(PNAS) of the first non-human primate study to use multiple,systemic dosing with
Calando's lead siRNA therapeutic candidate.
Calando is using its propri...
More>>